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The ORCHESTRA online questionnaire on “benefits and barriers to the use of QSAR methods” addressed the
academic, consultant, regulatory and industry communities potentially interested by QSAR methods in the context
of REACH. Replies from more than 60 stakeholders produced some insights on the actual application of QSAR
methods, and how to improve their use.
Respondents state in majority that they have used QSAR methods. All have some future plans to test or use QSAR
methods in accordance with their stakeholder role.
The stakeholder respondents cited a total of 28 models, methods or software that they have actually applied. The
three most frequently cited suites, used moreover by all the stakeholder categories, are the OECD Toolbox, EPISuite
and CAESAR; all are free tools.
Results suggest that stereotyped assumptions about the barriers to application of QSAR may be incorrect. Economic
costs (including potential delays) are not found to be a major barrier. And only one respondent “prefers” traditional,
well-known and accepted toxicological assessment methods.
Information and guidance may be the keys to reinforcing use of QSAR models. Regulators appear most interested
in obtaining clear explanation of the basis of the models, to provide a solid basis for decisions. Scientists appear
most interested in the exploration of the scientific capabilities of the QSAR approach. Industry shows interest in
obtaining reassurance that appropriate uses of QSAR will be accepted by regulators.Finding
The paper shows results on a questionnaire on the use
of in silico methods for the prediction of the properties
of chemical substances. All respondents are interested
on the in silico methods and there is no a priori barrier.
However, responses reveal different priorities on the use
and preferences on the properties modelled, depending
on the stakeholders: regulators, scientists, or industry
representatives. Freely available models, such as EPISuite,
OECD Toolbox, and CAESAR, are more frequently used.
Introduction
In recent years the EU has funded research into develo-
ping computer-based methods for evaluating the toxicity
of chemicals, called QSAR or ‘Quantitative structure-* Correspondence: mays.claire.orchestra@gmail.com
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reproduction in any medium, provided the oractivity relationship’ models. These computerized models
are potentially important in making it possible to evaluate
large numbers of chemicals (as required by the EU
REACH legislation) while also reducing the numbers of
tests on animals.
The ORCHESTRA project [1] is funded by the EC to
communicate some of the research findings to regulators,
industry users and others. The intention is to promote the
wider understanding, awareness and appropriate use of
QSAR methods.
Within ORCHESTRA we conducted a survey of stake-
holders to identify the perceived benefits, barriers and
needs in relation to the regulatory use of QSAR methods.
We produced a questionnaire addressing potential and ac-
tual users of QSAR models: regulatory bodies, industry,
scientists and consultants. Responses to the questionnaire
provide insight into:l Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methods
– The perceived benefits and attractions of QSAR
methods
– The current barriers to the use of QSAR methods
– The current professional and policy needs
– Stakeholders’ current sources of information on in
silico methods in toxicology.
Note that for simple convenience, the terms “QSAR”
and “in silico”, or “models” and “methods”, are used in-
discriminately in this report.
A fully detailed report [2] of the questionnaire study,
including aspects not considered in this brief article,
may be found online at the (identical) project websites:
www.orchestra-qsar.eu or www.in-silico-methods.eu.
Questionnaire and sample
The invitation to respond to the online questionnaire
took the form of a letter in English that was circula-
ted by email first to 280 potential respondents across
Europe and beyond, and then to a much larger set of
stakeholders. However, since the flow of responses was
small, a second questionnaire was created as a quick al-
ternative for professionals who might feel too busy to
respond to a survey. Questionnaire I contained 8 ques-
tions, while Questionnaire II had only 2–4. The period of
data collection was Sept 2010 – April 2011.
Both questionnaires can be viewed online at the pro-
ject websites mentioned above. Questionnaire I and II
yielded 33 and 29 responses respectively, 62 in total.
There was no overlap between the populations replying
to the two questionnaires.
The total sample is unfortunately too small to repre-
sent in detail the full population that was approached
for this survey. However, some trends or groupings in
response seem to emerge, and great care has been taken
to interpret these at an appropriate level.
Questionnaire I asked participants to designate the
context in which their research, development and/or
application of in silico methods take place. On the basis
of a careful examination of these descriptive data, three
categories were constructed:
 ACACON – Activity takes place in an
academic or consultancy context. Members of
this category display many different roles and
stakes within the REACH process, but they are
distinguished by the facts that they are not direct
employees of an industrial manufacturer of
chemical products, nor are they tasked as
protectors of public health. a13 subjects
 REGUL - Activity takes place in a governmental
regulatory context. Members’ primary stake andnational (or international) mission lie in protecting
public health or the environment. 12 subjects
 INDUS – Activity takes place within a
commercial industrial context. Members are
directly employed by manufacturers of chemical
products, and their company has a primary
economic stake in the outcome of specific
REACH dossiers. (A chemical manufacturers’
federation is also represented in this category).
8 subjects
As stated above, no claim is made to describe stake-
holder populations at large; the suggestive trends we ob-
serve in Questionnaire I replies would demand testing
on a larger survey population. This said, systematically
collected survey data from 33 specialists may be more
solid than anecdotal impressions. Finally, the interpreta-
tions offered here are highly coherent not only with the
actual professional experience of ORCHESTRA project
members but moreover with the in-depth interview
findings documented in other parts of the project.
These findings are provided on the ORCHESTRA web-
sites. Notably, on April 6th 2011 a workshop was held
entitled “REACH and QSAR: What can we learn from
case studies”; the summary available online recounts
needs for better understanding of the uses of QSAR
models, for better inter stakeholder communication,
and for training, all of which are borne out by the sur-
vey reported in the present article. Also online, the
extensive video interviews of academics, consultants, regu-
lators and industry representatives help to understand par-
ticular priorities among these different populations [www.
orchestra-qsar.eu or www.in-silico-methods.eu].
Data presentation
Because the sample is small, after discussion with scien-
tists and with laypersons we decided we should not
refer to percentages of response in our discussion of
results. Instead, an illustrative “green light” system of
presentation is chosen. This system is used throughout
and indicates in an intuitive way the relative strength or
proportion of response:
– When more than 3/4 of the population within a
given category chose the response option, that result
is communicated by a large green square
– When 1/2 to 3/4 of the population chose an option,
this is communicated by a large orange lozenge
– When 1/4 to 1/2 of the population chose an option,
this is communicated by a grey disc
– When less than one quarter of the population chose
an option, that is communicated by a small red dot
– Absence of reply is represented by a dash - .
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descending frequency of citation within the ACACON
category, followed by descending REGUL frequencies.
Results and discussion
Actual and projected future uses of QSAR
Specialist stakeholders (academics or consultants, regu-
lators, and industry users) were asked whether they now
use, or have in the past used/tested the methods, under
which conditions, and for which purposes. They were
asked to indicate the specific methods, models or soft-
ware applications used or tested.
The Questionnaire I data discussed below portray
effective experience today with applying in silico
methods, models and software. They also indicate sta-
keholders’ vision of how these methods will be used
tomorrow.Table 1 The QSAR models cited by respondents
Model, method, software
that have been used or
tested
ACACON
Σ (12 of 13 subjects replie
OECD QSAR Toolbox 16 7








ACD/Tox Suite 3 1
ToxBoxes 2 1
EQUATIONS from LITERATURE 2 1
OWN INTERNAL MODELS 2 1
Lazar 2 1
MultiCase 1 1
ChemAxon Marvin 1 1
Macromodel 1 1
Molcode Toolbox 1 1
OncoLogic 1 1
Sybyl 1 1
Danish EPA QSAR database 3




PBKB (SimCYP & MCSim) 1
PBT Profiler 1
SoilFug 1QSAR methods: Used or not?
Among respondents to the detailed Questionnaire I, the
majority (20) states that they have directly used or tested
QSAR methods. Of the 33 respondents in total, a single
one (ACACON) claims that this use was “not successful”.
All respondents indicate that they have some future
plans to test or use QSAR methods.
Actual models, methods and software in use
Questionnaire I collected free text responses to the query
“Which models, methods and software have been used or
tested?” Twenty-eight of 33 respondents reply, citing in
each case more than one model or software suite.
Table 1 shows the methods cited, arranged by des-
cending frequency of citation among the ACACON
respondents, followed by frequency of citation among
REGUL, then among INDUS.Number of citations
REGUL INDUS
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suites are cited by the population responding to the sur-
vey. The three most frequently cited suites are: OECD
Toolbox, EPISuite and CAESAR. These three suites are
used by all three stakeholder communities. CAESAR is
the only software not developed within a regulatory ini-
tiative. Each of these three suites is available as free-
ware. This finding may indicate a preference for free,
widely accessible systems.
Domains of past application, and the endpoints
investigated
Overall, all categories of stakeholder respondents are
simultaneously investigating different domains of appli-
cation. The proportion of actual application by area for
the respective stakeholders is shown in Table 2 (ordered
by descending importance according to the expressed
view by ACACON).
The ACACON community shows the highest rate of
application in the area of physico-chemical properties
of compounds. REGUL and INDUS appear at this time
to be lending somewhat less attention to the assessment
of physico-chemical properties through QSAR. INDUS
also seems to “lag” behind the other categories in appli-
cations to human toxicology and environmental fate
properties.
Endpoints that have benefitted from QSAR applica-
tions among our population are reported in Table 3.
This table does not indicate any hierarchy of endpoints.
However, endpoints that were mentioned several times
across subjects (within a single stakeholder family) are
underlined.
Domains of future application, and the endpoints targeted
All respondents indicated that they have plans for fu-
ture applications even if they have not yet tested in
silico methods. Our data suggest overall that all three
stakeholder populations today are in a phase of experi-
mentation with QSAR models. Their practice and activ-
ity are not “set” at this time.Table 2 Domains of past application of in silico methods




EcotoxicologyRegulators overall and within subjects indicated that
there would be a slight tendency to transfer or add atten-
tion to environmental fate and ecotoxicology endpoints.
Functions addressed by past applications
Table 4 considers the functions to which the stake-
holders have applied QSAR models.
ACACON presently appear to prefer QSAR tools as
time-saving devices and fundamental research devices.
They also acknowledge regulatory data demands.
Among REGUL, QSAR is principally applied to provide
supporting information. Use for fast evaluation and as part
of the weight-of-evidence approach is also acknowledged.
A non negligible proportion of REGUL states “none/
not sure” about the pertinent functions – but an exam-
ination of individual data shows these respondents have
already tried QSAR methods (generally the OECD Tool-
box). This confessed ignorance by regulators regarding
functions may simply flag a need to develop their famil-
iarity with the tools.
Among INDUS (like ACACON) fast triage applica-
tions are important – more so than in the regulatory
community. The profile for prioritisation uses is similar
if less pronounced. INDUS and REGUL give comparable
importance to the use of QSAR for providing supporting
information. INDUS match other stakeholders in their
acknowledgement of weight-of-evidence uses, but differ
by appearing to leave aside key study applications.
INDUS more than REGUL utilize QSAR for research
and development for the evaluation of toxicity.
Functions addressed in planned (future) applications
The respondents of every category appear to recognize
that in silico methods will be applied more broadly in
the future. Some stakeholders are gearing up to use, test
or develop these methods themselves; but even those
who today do not plan to use them clearly recognize
their growing importance.
Regulators appear to anticipate a slight widening of
functionality.ACACON REGUL INDUS
Table 3 The QSAR models used by respondents
Sample endpoints mentioned from actual applications of QSAR
Stake-holder group Physico-Chemical Properties Human Toxicity Ecotoxicity Environmental
Properties




mouse SCE, mouse COMET)
Carcinogenicity Teratogenicity
Acute toxicity (mammals)






toxicity (Daphnia) Acute fish















Carcinogenicity Aquatic toxicity Bioaccumulation/ BCF
(6 of 12 subjects
replied)
Reproductive toxicity Daphnia reproduction Degradation (DT50)
Mutagenicity/ genotoxicity
(also addressing metabolites)
All ecotox part of EPI Suite
(Aquatic toxicity acute and










Acute aquatic invertebrate toxicity
(Daphnia) (LC50 daphnia magna as
supporting information) Fish toxicity
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application by regulators for the needs of prioritisation.
Perceived benefits and attractions of QSAR methods
Scientists, regulators, and industry users were asked their
view on the main reasons to use QSAR methods.
The data in Table 5 give a picture of the differential
attractions and benefits of the methods in the perception
of these specialist stakeholders.Table 4 Functions addressed by past applications of in silico m
Functions addressed by actual (past) applications
Fast evaluation of the properties of chemicals of interest
Research and development, for the evaluation of toxicity
Regulatory requirements - as supporting information
Regulatory requirements - as part of a weight-of-evidence approach
Prioritisation of compounds for further analysis
Regulatory requirements - as the key study
None / not sureThere is a primary consensus across stakeholders that
going forward, QSAR methods are very attractive for
identifying and prioritising substances of concern. For
ACACON and REGUL in particular this perception is
quite strong.
Also consensual across stakeholders, albeit at a lower
level, is the view that these methods offer some attrac-





Table 5 Main reasons to use QSAR methods going forward
Main reasons ACACON REGUL INDUS
To identify and prioritise substances of concern.
To improve the response to regulatory requirements such as risk assessment
and classification and labelling.
To reduce the use of vertebrates in experiments - to meet regulatory requirements.
To reduce the time and costs of experiments.
To assess potentially thousands of chemicals simultaneously
To reduce the use of vertebrates in experiments - to meet our own ethical policies.
To address endpoints for which animal models are not fully accepted.
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risk assessment, classification and labelling will be well
addressed by QSAR methods, whereas INDUS appear
less convinced.
INDUS enthusiastically endorse in silico to reduce the
laboratory use of vertebrates to meet regulatory requi-
rements, an enthusiasm diminishing somewhat in the
view of ACACON and quite modest in the view of
REGUL.
One regulator explained:
 “Reduction of vertebrate testing is a major goal,
however, secondary to improved risk management
which is the reason why I didn't tick the two boxes
[concerned]”.
The benefit of in silico methods to address in-house
ethical requirements on animal use is most attractive to
industry and ACACON; understandably this feature is
less attractive to REGUL.
REGUL find in silico methods more interesting than
do ACACON and INDUS stakeholders to address end-
points for which animal models are not fully accepted.
Comments from ACACON highlighted two further
attractions of in silico methods:
 “To supplement the information level for lower
tonnage chemicals with limited test information
requirements”
 “As a ‘glue’ between in vitro data in ITS approaches”.
Current barriers to the use of QSAR methods
This section reports findings from both Questionnaires
I and II.Specialist stakeholders (consultants, academics, regula-
tors, and industry users) were asked what prevents or
limits their use of QSAR methods.
Generic barriers
Respondents to the simplified Questionnaire II who have
not used QSAR are in fact waiting for a chance to try
out the methods. The strong majority said they were
“interested” and none was hostile to the methods. Over-
all the results suggest that persons already interested
and whose role allows them to apply the methods may
be very open to opportunities to do so.
The varied replies to Questionnaire I as to what pre-
vents or limits the use of in silico methods revealed no
predominant barrier. Just 3 REGUL, and one ACACON
or INDUS, stated that QSAR methods are “not a priority
for his/her organization”. Only one of 33 respondents
expressed preference for traditional, well-known and
accepted methods. This striking finding suggests that
such a preference is not a drag on application of QSAR
today. The next section suggests that better information
and guidance may be the key to reinforcing in silico
uses.
Needs for information or guidance
Stakeholders indicated areas in which more information
or regulatory guidance might overcome barriers to the
use of QSAR models. While all categories called for more
information or guidance, differential knowledge gaps are
described by these specialist stakeholders. Table 6 shows
the results about the information needs.
Interestingly, REGUL answers focus on pragmatic ap-
plication. Replies suggest that their primary need is for
good grasp of software outputs (the results of the model,
Table 6 Needs for information or guidance
Main option/sub option ACACON REGUL INDUS
All proportions are calculated on total stakeholder subsample
We need more information and/or regulatory guidance . . .
to assess whether a model can be viewed as scientifically valid and adequately documented;
to be able to use the technical software, and understand the outputs from it;
to know how to integrate different kinds of results from different methods into a submission;
to know what QSAR models are available or appropriate for our work;
to know more about when and how QSAR / in silico methods can be used.
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mation helping to assess the confidence they may place
in QSAR tools, and identification of appropriate uses of
the models. ACACON focus more on the scientific
aspects. INDUS responses here seem to suggest that
they need reassurance on the model acceptability and
pointers to the best available models.
Opening the way forward to increased use of in silico methods
Specialist stakeholders were asked what would help
them to use QSAR methods, and what in their view will
have most impact on the wider acceptance and use of
these methods.
What would facilitate use of QSAR/in silico methods
In this question stakeholders reported items that could
favour more use of QSAR methods. Table 7 shows the
results.
REGUL clearly place emphasis on aspects that are less
outstanding to ACACON or industry. Regulators’ answers
point to a desire for a documented, reasoned, exemplified
and standardized approach. This is coherent with the
results seen above on knowledge needs.
The ACACON sector here places emphasis on prag-
matic access to the right tools and demonstration of
their successful application.
INDUS’ few replies to these questions seem to align
more with ACACON than with REGUL. However,
INDUS seem here to be most attracted by a kind of
automated, standardized and simplified process. INDUS
users made detailed suggestions that highlight the po-
tential value of networking, mutuality of expertise, and
cooperation:
 “Better databases for mining particularly repeat dose
endpoints - need agreement on common format -way to deal with proprietary information - resources
to shred data and get it entered - broad agreement to
collaborate and enter data”
 “Definition of expert network in QSAR/in silico
methods”.
Views of what will have the most impact on acceptance of
QSAR methods
Stakeholders ranked measures that could foster the wider
acceptance of QSAR methods (Table 8).
There is consensus across sectors that in order to foster
use of QSAR, industry must demonstrate successful actual
applications; ACACON is particularly convinced of this
pragmatic assertion. All sectors also affirm that case study
evidence of the quality and reliability of in silico methods
will foster their greater use. In this way, a democratic,
evidence-based demonstration, with expert quality assur-
ance in the background, emerges as perhaps the best way
to trigger greater use, rather than reliance on high-profile
leadership or on trademarking.
Conclusion and recommendations
The full set of replies to the ORCHESTRA online question-
naires makes it clear that there is no a priori refusal of
QSAR models. On the contrary, stakeholders in the scien-
tific, regulatory and industry sectors are keen take oppor-
tunities to apply in silico methods. However, across sectors
a considerable need is expressed for “more information or
regulatory guidance” on using and applying these methods.
Varying knowledge demands are expressed by the differ-
ent stakeholders. Scientist and consultant respondents are
interested in both technical and scientific aspects of QSAR
applications, and they particularly want information that
will help to gauge the level of confidence that may be
placed in a model. Regulatory respondents on the other
hand assign slightly less concern to the scientific validity
Table 7 Facilitating the use of QSAR methods
What would help you to use QSAR / in silico methods? ACACON REGUL INDUS
Seeing good examples of industry using in silico methods successfully
(in documentary video, industry events, online reports and trade magazines).
Lists and reviews of the available models, with information on where to access them.
Examples from the regulators about acceptance of / enthusiasm for in silico methods
Seeing more peer-reviewed journal articles about the practical applications of
in silico methods, illustrated by case studies.
Clear guidelines for reporting toxicity results from in silico methods (maybe as an
automatic report generator within the software that matches the submission format).
Clear standardisation of the ways in which individual QSAR models and their appropriate
uses are described, and their applicability domains are defined.
Support and guidance from laboratories with expertise in the uses of QSARs.
Examples of the reasoning and transparent documentation required for submissions.
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of appropriate applications in view of REACH. Detailed
survey results [2] indicate that they seek a good grasp of
software outputs (the results of the model, and their
meaning). Industry respondents want reassurance that the
scientific quality of a given tool is acceptable; next they
want pointers to the best available QSAR models. They do
not ask for technical information about software, nor for
guidance about when and how QSAR can be used.
Given the fact that regulators are the primary actors in
acceptance of QSAR models, initiatives should address
regulatory information needs as a main target. More
detailed attention by developers and consultants to the
process requirements of REACH could be valuable. A good
model and its suite of tools are not sufficient, if the model
is not described and if output components are not trans-
parent. On the basis of these indications, ORCHESTRA,
together with the project ANTARES [3], has promoted the
web site VEGA (www.vega-qsar.eu), which provides aTable 8 Measures to foster improved acceptance of QSAR me
What will have the most impact on the wider acceptance of QSAR/in si
Industry using in silico methods more, and producing high quality results.
Case study research evidence of the quality and reliability of QSAR methods.
Use by high-profile companies / organisations, and in cases with high visibili
The monitoring, review and updating of models by specialist QSAR laborator
The trademarking of models by trusted software companies or organisationshighly detailed explanation on the analysis of model results
for a given substance.
At the time of the survey ECHA had published some
documents on the use of alternative methods, including
QSAR [4]. Questionnaire replies may mean that these
documents were not well known, or that they were not
yet sufficient. We note that the ECHA guidance docu-
ments benefit from updates and that a series of fact
sheets is available.
Respondents emphasized the importance of conduct-
ing case studies, consolidating experience with model
use. Similarly, there is consensus across sectors that in-
dustry demonstrating successful actual applications will
have a large impact on broadening use of in silico meth-
ods. “An important factor in the confidence building is to
simply start using the tools, both industry and regulatory
bodies, to see for themselves how they work.” This is in-
deed a promising direction, and initiatives should ad-
dress this.thods
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mutualising expertise and cooperation are suggested by
respondents as aids to bring industry up to speed in ap-
plying the methods.
Responding to information demands also means increas-
ing training initiatives. ORCHESTRA is actively working
for this; detailed material can be found at the ORCHES-
TRA web site.
Endnote
aA priori, the questionnaire offered two categories se-
parating academics and consultants. However, on exam-
ination of complementary descriptive data provided by
persons in these two categories, it became clear that
many academics were also consultants in some capacity.
It was decided that in context, the more important dis-
tinction was indeed the role difference between these
intellectual practitioners, those whose primary stake is
health protection, and those serving the industrial stake.
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